- Home
- LNG vs TAK Comparison
LNG vs TAK Comparison
Compare LNG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNG
- TAK
- Stock Information
- Founded
- LNG 1983
- TAK 1781
- Country
- LNG United States
- TAK Japan
- Employees
- LNG N/A
- TAK N/A
- Industry
- LNG Oil/Gas Transmission
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- LNG Utilities
- TAK Health Care
- Exchange
- LNG Nasdaq
- TAK Nasdaq
- Market Cap
- LNG 52.0B
- TAK 47.0B
- IPO Year
- LNG 1997
- TAK N/A
- Fundamental
- Price
- LNG $233.86
- TAK $14.37
- Analyst Decision
- LNG Strong Buy
- TAK
- Analyst Count
- LNG 13
- TAK 0
- Target Price
- LNG $247.54
- TAK N/A
- AVG Volume (30 Days)
- LNG 1.8M
- TAK 2.0M
- Earning Date
- LNG 05-08-2025
- TAK 05-08-2025
- Dividend Yield
- LNG 0.86%
- TAK 4.08%
- EPS Growth
- LNG N/A
- TAK N/A
- EPS
- LNG 13.71
- TAK 0.45
- Revenue
- LNG $16,645,000,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- LNG $32.83
- TAK $0.87
- Revenue Next Year
- LNG $12.75
- TAK $1.69
- P/E Ratio
- LNG $17.04
- TAK $63.69
- Revenue Growth
- LNG N/A
- TAK 7.45
- 52 Week Low
- LNG $153.03
- TAK $12.58
- 52 Week High
- LNG $257.65
- TAK $15.37
- Technical
- Relative Strength Index (RSI)
- LNG 53.99
- TAK 40.48
- Support Level
- LNG $225.66
- TAK $14.22
- Resistance Level
- LNG $244.05
- TAK $15.43
- Average True Range (ATR)
- LNG 6.27
- TAK 0.20
- MACD
- LNG 0.26
- TAK -0.08
- Stochastic Oscillator
- LNG 49.70
- TAK 11.98
About LNG Cheniere Energy Inc.
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.